12/17/2013 On December 17, 2013, the U.S. District Court for the District of Delaware issued a ruling finding that Lupin’s genericAbacavir Sulfate; Lamivudine; Zidovudine Tablets do not infringe U.S. Patent No. 6,417,191 (‘the ‘191 patent’). In the litigation, ViiV Healthcare UK Ltd. and ViiV Healthcare Co. sought to prevent Lupin’s marketing of a generic equivalent to Trizivir® (Abacavir Sulfate; Lamivudine; Zidovudine). After a 4-day bench trial, the District Court concluded that Lupin’s generic Abacavir Sulfate; Lamivudine; Zidovudine Tablets do not infringe the ‘191 patent.
This victory continues to place RMMS at the forefront of generic challenges to brand pharmaceutical patents.
Deanne Mazzochi, Paul Molino, Rachel Pernic-Waldron and Patrick Kilgore tried the case for Lupin.